Twenty-eight of 30 participants had rabies virus neutralizing antibody titers \u22650.5 IU\/mL on day 14 after HRIG150 postexposure prophylaxis<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Feb. 10, 2021 (HealthDay News) — For pediatric patients, human rabies immunoglobulin (HRIG150) is well tolerated and effective as part of postexposure prophylaxis (PEP), according to a study published in the March issue of Human Vaccines & Immunotherapeutics.<\/em><\/p>\n Nicholas Hobart-Porter, D.O., from the University of Arkansas for Medical Sciences in Little Rock, and colleagues conducted a two-center, open-label trial evaluating HRIG150 as part of PEP in patients aged younger than 17 years with suspected or confirmed rabies exposure. Thirty participants received 20 IU\/kg HRIG150 infiltrated into the detectable wound site with any remainder injected intramuscularly, concomitantly with a four-dose series of rabies vaccine.<\/p>\n The researchers observed no serious adverse events, rabies infections, or deaths. Within 14 days following administration, 21 participants experienced 57 treatment-emergent adverse events (TEAs). Twelve participants experienced 13 adverse events that were deemed related to treatment. The TEAs were all of mild severity. Twenty-eight participants had rabies virus neutralizing antibody titers \u00e2\u0089\u00a50.5 IU\/mL on day 14.<\/p>\n “Results of this study confirm the safety profile and efficacy of HRIG150 in preventing rabies in pediatric patients when used as part of a PEP regimen,” the authors write. “We conclude that HRIG150 is appropriate for use as a lifesaving component of PEP in pediatric patients.”<\/p>\n Several authors disclosed financial ties to Kamada Ltd. and Kedrion Biopharma Inc., which provided study funding.<\/p>\n